key: cord-0533052-0e6aqy17 authors: Abuin, Pablo; Anderson, Alejandro; Ferramosca, Antonio; Hernandez-Vargas, Esteban A.; Gonzalez, Alejandro H. title: Dynamical Characterization of Antiviral Effects in COVID-19 date: 2020-12-31 journal: nan DOI: nan sha: 18f1c062b7fb7a1e61a214ea4cdfdf54d1ab0205 doc_id: 533052 cord_uid: 0e6aqy17 Mathematical models describing SARS-CoV-2 dynamics and the corresponding immune responses in patients with COVID-19 can be critical to evaluate possible clinical outcomes of antiviral treatments. In this work, based on the concept of virus spreadability in the host, antiviral effectiveness thresholds are determined to establish whether or not a treatment will be able to clear the infection. In addition, the virus dynamic in the host -- including the time-to-peak and the final monotonically decreasing behavior -- is chracterized as a function of the treatment initial time. Simulation results, based on nine real patient data, show the potential clinical benefits of a treatment classification according to patient critical parameters. This study is aimed at paving the way for the different antivirals being developed to tackle SARS-CoV-2. The main contribution of this work -that can be seen as an extension of [23] -is to provide a formal mathematical analysis of the COVID-19 dynamic under the effect of antiviral treatments, which may help to understand how to schedule the different therapies in function of the host parameters. A quantitative classification stating whether or not an antiviral will be effective -in terms of its capability to died out the virus in a reasonable period of time -is made, showing that their effectiveness could vary significantly between subjects. After the introduction given in Section 1 the article is organized as follows. Section 2 proposes a general three-states "in host" model to represent COVID-19 infection dynamic and formalizes the concept of virus spreadability. Section 3 characterizes the equilibrium sets of the system, and its asymptotic stability, for the untreated case (i.e., when no pharmacodynamic is considered), considering the system from the infection time t = 0. Then, in Section 4, the pharmacodynamic of antivirals is included, to analyze their effectiveness to avoid the virus to spread in the host. Both, the inhibition effect on the replication rate of the virus and the inhibition effect on the infection rate of healthy cells are studied. In Section 6, the results of Section 4 are extensively demonstrated by simulating different treatments scenarios for nine patients from the literature. Finally, Section 7 gives the discussion of the work, while several mathematical formalism -necessary to support the main results of article -are given in Appendix 8. Mathematical models of within-host virus dynamic helps to improve the understanding of the interactions that govern infections and permits the human intervention to moderate their effects [24] . Basic models usually include the cells the pathogen infects, the pathogen particles, and their life cycle [25] and, opposite to one can expect, they vary little in its structure from one infectious disease to another. Indeed, the well known target cell-limited models (i.e., models that incorporate the immune response just as a parameter) was successfully used to represent and control HIV [26, 27, 20] , influenza [28, 16, 29, 30] , Ebola [18] and dengue [31, 32] , among others. A main distinction between target cell models can be done according to the virus life cycle [25] : chronic infection models (long-lived and persistent virus in comparison with cells life cycle) include production and death rates of healthy/susceptible cells, while acute infection models (shortlived virus) only consider the clearance of susceptible cells produced by the infection. This latter -which was firstly introduced in [16] for the influenza -is used to describe the COVID-19, as it is detailed next. In this paper we consider the following mathematical model [12, 23] : where U (cell), I (cell) and V (copies/mL) represent the uninfected cells, the infected cells, and the virus concentration. The parameter β (mLday −1 /copies) is the infection rate, δ (day −1 ) is the death rates of I, p ((copies)/(cellmL)day −1 ) is the viral replication, and c (day −1 ) is the viral clearance rate. The effects of immune responses are not explicitly described in this model, but they are implicitly included in the death rate of infected cells (δ) and the clearance rate of virus (c) [16] . System (2.1) is positive, which means that U (t) ≥ 0, I(t) ≥ 0 and V (t) ≥ 0, for all t ≥ 0. We denote x(t) := (U (t), I(t), V (t)) the state vector, and value V 0 at t = 0 (formally, V (t) has a discontinuity of the first kind at t 0 , i.e., lim t→0 − V (t) = 0 while lim t→0 + V (t) = V 0 > 0). This way, for the time after the infection, the virus may spread or being clear depending on its infection effectiveness. To properly determine what such a spread means, the following (mathematical) definition is given Definition 1 (Spreadability of the virus in the host). Consider system (2.1) , constrained by the positive set X, with V (t) = 0, I(t) = 0, and U (t) = U 0 > 0, for t < 0. Consider also that at time t = 0, V (t) jumps from 0 to a small positive value V 0 . Then, it is said that the virus spreads (in some degree) in the host for t ≥ 0 ifV (t) > 0 for some t > 0. If the virus does not spread in the host, it is said that it is cleared for t ≥ 0. Definition 1 states that the virus spreads in the host, for t ≥ 0, if V (t) increases at some time t > 0, and so, given that lim t→∞ V (t) = 0 (as it is stated later on in the article), it reaches at least one local maximum at some positive time. On the other hand, the virus is cleared for t ≥ 0 if V (t) is strictly decreasing for all t > 0, which means that V (t) has neither local minima nor local maxima at any t > 0 (latter on it is stated that V (t) has at most one minimum and one maximum). An infectious disease can be related to the virus peak and/or the period of permanence of the virus in the host [18] , and both effects are related to an increase of the virus load at some time after the infection. This is the reason why the spreadability is defined based on the virus positive derivative. A second reason supporting Definition 1 is its use in the determination of antiviral effectiveness (Section 4). Antivirals able to clear the virus can be considered effective. In what follows, time t = 0 will be considered as the infection time, i.e., the time when a small amount of virus enters the host. To formally establish conditions under which the virus does or does not spread for t > 0, some basic concepts need to be defined. The first one is the well-known basic reproduction number. Definition 2. The within-host basic reproduction number R is defined as the number of infected cells (or virus particles) that are produced by one infected cell (or virus particle), over a course of its life-span. Its mathematical expression is given by: Particularly, for t = 0, this number describes the number of virus particles produced by a virus particle when a small amount of virus, V 0 , is introduced into a healthy stationary population of uninfected target cells, U 0 , A second number, which is closely related to the first one, is the critical value for the susceptible cells such that the virus starts to decrease. which for fixed system parameters β, p, δ and c is a constant. Note that U (t) < U c if and only if R(t) < 1, for every t ≥ 0. The basic reproduction number R(t) and the critical number U c completely describe dynamic (2.1), as it is shown in the next sections. In this section, the infection evolution from the beginning (time t = 0) is considered without antiviral treatments. A detailed analysis of the dynamical behaviour will help us to properly understand, in next sections, the antivirals effects. By equalingU ,İ andV to zero, in (2.1), it can be shown that the system only has free virus equilibrium of the form x s = (U s , 0, 0), with U s being an arbitrary positive value, i.e., U s ∈ [0, ∞). Thus, there is only one equilibrium set, which is a healthy one, and it is defined by According to [23] , set X s can be partitioned in two subsets, and being X 1 s asymptotically stable and X 2 s unstable, as stated in the next theorem. Theorem 3.1 (Asymptotic stability). Consider system (2.1) constrained by the positive set X. Then, the set X 1 s defined in (3.2) is the smallest asymptotically stable (AS) equilibrium set, with a domain of attraction given by X . Proof: The proof is given in [23] , Theorem 3.3. Theorem 3.1 establishes that neither single equilibrium points x s ∈ X 1 s nor subsets of X 1 s are AS. Furthermore, any trajectory starting at non-equilibrium states tends to a state in X 1 s , which depends on the initial conditions. This has critical implications on the controllability of the system, provided that X 1 s is the minimal formal equilibrium target set to be used in a control strategy (based, for instance, on antiviral treatments). Furthermore, as stated in [23] , if we define U ∞ = lim t→∞ U (t), I ∞ = lim t→∞ I(t) and V ∞ = lim t→∞ V (t), then, I ∞ = 0, V ∞ = 0, and where W (·) is the Lambert function, and R 0 = U 0 βp cδ and K 0 = β c ( p δ I 0 − V 0 ) are constants depending on the initial conditions. Given that W (−R 0 e −(R0+K0) ) ∈ (0, 1) for positive values of R 0 and K 0 , this means that the only state that does not necessarily converge to zero, i.e. U , converges to a value smaller than U c , which depends on U 0 , I 0 , V 0 . See [23] for further details. The general behavior of system (2.1) can be analyzed according to the initial conditions and parameter values. Property 1, next, shows some general characteristics of the susceptible cells as time goes to infinity ( [23] ). Property 1. Consider system (2.1), constrained by the positive set X, at the beginning of the infection, i.e., U (0) = U 0 > 0, I(0) = 0 and V (0) = V 0 > 0 (i.e., x(0) = (U (0), I(0), V (0)) ∈ X ). Consider also that V 0 is small enough. Then, Proof: The proof -which is given in [23] , Property 2 -follows from the fact that K 0 ≈ 0 for the selected initial conditions, and, so, according to (3.4) , U ∞ ≈ −U c W (−R 0 e −R0 ). Figure 1 shows a phase portrait of system (2.1), with parameters β = 0.5, δ = 0.2, p = 2 and c = 5, which provide U c = 1. As it can be seen, every initial state, even those that are close to the axes (U, 0, 0) with large values of U , tends to X 1 s as t → ∞. The following theorem characterizes the whole dynamic of system (2.1) from the start of the infection, in terms of the variables peaks. Theorem 3.2 (Virus behavior from the infection time). Consider system (2.1), constrained by the positive set X, at the beginning of the infection, i.e., U (0) = U 0 > 0, I(0) = 0 and V (0) = V 0 > 0 (i.e., x(0) = (U (0), I(0), V (0)) ∈ X ). If the virus spreads (according to Definition 1), then R 0 > 1 + α(0), for some α(0) > 0 (or, the same, U 0 > U c ) and there exist positive timesť V ,t I , t c andt V , such thať t V 0 is given by R 0 < 1 (or, the same, U (0) < U c ). This condition, adapted for the time an antiviral treatments is initiated, will serve in the next section to determine their effectiveness. Remark 4. Consider that the assumptions of Theorem 3.2 hold. If the virus clearance is significantly faster than the infected cell death (c >> δ), as it is usually the case (see [15] , Equation (4) , [33] , [34] , [35] ) the three-states system (2.1) can be approximated by the following two-state equations: where the infected cell state is given by I(t) ≈ c p V (t). Note that equation (3.5.b) can be written aṡ V (t) = (R(t) − 1)δV (t). Then, according to Theorem 3.2, it is easy to see thatt V → t c from the right andt I → t c from the left when (c/δ) → ∞, i.e., the peaks of V and I tend to occur simultaneously, at time t c . Figure 1 shows a phase portrait of system (2.1) with a rather unrealistic parameter values ( β = 0.5, δ = 0.2, p = 2 and c = 5) but useful to exemplify how, after a relatively short time (and provided that c > δ), the system reaches the manifold defined by the condition I(t) = c p V (t). This behavior can also be seen in the time-behavior plot in Figure 2 . shows U (t), I(t), V (t) and R(t) time evolution, for β = 0.5, δ = 0.2, p = 2 and c = 5, and initial conditions such that R 0 > 1 + α(0) and R 0 < 1 + α(0) (with α(0) ≈ 0). As it can be seen, the results in Theorem 3.2 and Remarks 4 and 3 are confirmed by the simulations. All these results are also confirmed by the nine real patients identified and simulated in Section 5 and 6 (see, particularly, Table 2 and Figure 5 ). The goal of this section is to formally consider the effect of antivirals into system (2.1) to obtain a controlled system, i.e. a system with certain control actions -given by the antivirals -that allows one Figure 1 : Phase portrait of system (2.1) with parameters β = 0.5, δ = 0.2, p = 2 and c = 5, for different initial conditions not necessarily representing realistic cases. Empty circles represent the initial state, while solid circles represent final states. The red hyperplane corresponds to U (t) ≡ Uc (i.e., the critical value of U , when R(t) = 1) while the blue hyperplane corresponds to the fast manifold in which I(t) and V (t) are proportional (.i.e, I(t) = c/pV (t)). Note that only the initial states with U0 > Uc = 1 corresponds to scenarios with R0 > 1. to (even partially) modified the whole system dynamic according to some control objectives. Antivirals have the potential to inhibit the virus replication, reducing the advance of the infection over the target cells of infected host (i.e.: epithelial cells in the respiratory tract for H1N1 [16] ). Several antivirals are being tested for COVID-19 treatment, with different results concerning both, their inhibition effect on the virus replication and their toxicity. Among them, Remdesivir, Favipiravir, Umifenovir, Chloroquine, Oseltamivir, etc. [36, 10, 37, 38, 39] can be mentioned. The antiviral effect can be modeled as a reduction of the virus infectivity in the presence of inhibitors (by reducing the infection rate β) and/or as a reduction in the replication of infectious virions (by reducing the replication rate p) [4, 15] . In any case, the effectiveness of a treatment is limited and depends on the patient parameters (which in turn depends on his/her clinical state). Next, two different inhibition effects η β (t) and η p (t) are considered, one affecting the infection rate β and the other affecting the replication rate p. It is assumed that the virus spreads in the host from the infection time t = 0, i.e., V (t) reaches a maximum at some timet V if no treatment is initiated. The controlled system (i.e., the system considering antiviral treatment) can be written as: where η β (t) ∈ [0, 1) and η p (t) ∈ [0, 1) are assumed to jump from 0 to the new value η β and η p at the treatment time t tr (i.e., the pharmacokinetic of the antivirals is assumed to have time constants significantly smaller than the ones of system (2.1), and, so, it is neglected) being η β ∈ [0, 1) and η p ∈ [0, 1) constant values representing the full inhibition treatment effect. The treatment time t tr is assumed to be between the minimum and maximum time of V , i.e.,ť V < t tr t V ). The full antiviral effect η p and η β are limited by the inhibitory potential of the drug (expressed in terms of EC 50 , or drug concentration for inhibiting 50% of antigen particles) and its cytotoxic effect (expressed in terms of IC 50 , or drug concentration which causes death to 50% of susceptible cells) [38, 40] . As the antiviral treatment reduces the system parameter in some amount, it will quantitatively modify the virus behavior. Particularly, the virus peak time will be modified fromt V (untreated patient case) tô t V,tr (treated patient case). However, given that the treatment is initiated when the virus is increasing (i.e., betweenť V andt V ), then the new peak will occur at the same time or after the treatment time, i.e., t V,tr ≥ t tr . This way, even when the virus peak will always be smaller with a treatment (smaller peaks are obtained for smaller values of p and β), the time at which this peak takes place can be smaller or greater than the one without any treatment. This effect, usually disregarded in many studies concerning the effectiveness of antivirals, could be critical to define whether or not a given antiviral is able to impede a severe disease. Indeed, in some cases, antivirals significantly delay the virus peaks, largely increasing the time of permanence of the virus in the host. In order to qualitatively assess antiviral effectiveness according to the time of the virus peak, the following classification is made: Definition 4 (Antiviral treatment effectiveness). Consider system (4.1), constrained by the positive set X, such that the virus spreads in the host from time t = 0, which implies that: U (0) > U c , I(0) = 0 and V (0) > 0. Consider also that, at time t tr , withť V < t tr U c , I(0) = 0 and V (0) > 0. Consider also that, at time t tr , withť V < t tr η c p (t tr ) (or η β > η c β (t tr )) then the maximum of V (t) occurs at t tr , which is smaller thant V by hypothesis. In this case the antiviral treatment is effective. ii. for two antiviral treatment, 1 and 2, with inhibition effects η 1 , for all t ∈ (t tr , t * ], being V 1 (t) and V 2 (t) the virus corresponding to treatments η 1 p and η 2 p , respectively. In this case both treatments are effective, and treatment 2 is more efficient than treatment 1. iii. if the inhibition effect is such that η p < η c p (t tr ) (or η β < η c β (t tr )), then the virus reaches a maximum at a timet V,tr > t tr . Furthermore, there exists a time t e = t e (η p , t tr ) -denoted as early treatment time -such thatt V,tr >t V for t tr ∈ (ť V , t e ]. In this case the antiviral treatment is ineffective. iv. for two antiviral treatment, 1 and 2, with inhibition effects η 1 tr the virus maximum time corresponding to treatments η 1 p and η 2 p , respectively. In this case both treatments are ineffective, but treatment 1 is more efficient than treatment 2, which is a rather counter-intuitive fact. Sketch of Proof: For the sake of simplicity and clarity the proof is based on the approximation of system (2.1) described in Remark 4. In such a case, system Only antiviral treatments affecting parameter p is considered, since the results follows from conditions on R(t) and parameters β and p affect R in the same way. i. Sinceť V < t tr 1 for t < t tr . Given that η p > η c p (t tr ), then by (4.3) R(t) jumps to a value smaller than one at t tr , i.e., R(t − tr ) > 1 and is increasing when the treatment is initiated, its maximum occurs at t tr . ii. Let us consider that for all t ≥ t tr , V i (t) and U i (t) are the virus and the susceptible cells for treatment (note thatV is not defined on t tr ). As it is shown in Section 6.1, for real data patients, t * is large enough such that V (t * ) ≈ 0. iii. Sinceť V < t tr 1 for t < t tr . Given that η p < η c p (t tr ), then by (4.3) R(t) jumps, at t tr , from , which is still greater than one; i.e., R(t − tr ) > R(t tr ) > 1. From the fact that R(t tr ) > 1, it follows thatV (t tr ) > 0, and given that R(t) is decreasing for t > t tr , there exists a timet V,tr > t tr such that R(t V,tr ) = 1, in which case, it iṡ This means that V (t) reaches a maximum at timet V,tr > t tr . Now, we need to prove that there exist a time t e (η p , t tr ) such that for t tr ∈ (ť V , t e ) it ist V,tr >t V . According to Lemma 1, there exists a time t e = t e (η p , t tr ), smaller thant V , such that for a treatment time t tr ∈ (ť V , t e ],t V,tr is a decreasing function of R(t tr ), for R(t tr ) > 1. This implies that smaller values of R(t tr ) (greater values of η p ) correspond to larger times at which R(t), t > t tr , reaches 1, i.e., smaller values of R(t tr ), correspond to larger values oft V,tr . So, from the fact that R(t − tr ) > R(t tr ) (being R(t − tr ) the value of R at t tr if no treatment is applied), it follows thatt V,tr >t V > t tr , for t tr ∈ (ť V , t e ]. As it is shown in Sections 6.1 and 6.2, for real data patients, (the maximal) t e is close tot V . iv. Since η 1 p < η 2 p < η c p (t tr ), by hypothesis, then 1 < R 2 (t tr ) < R 1 (t tr ), being R 1 (t tr ) = U(ttr )p(1−η 1 p )β cδ and R 2 (t tr ) = U(ttr )p(1−η 2 p )β cδ . Therefore, by following the same steps of the previous item, it follows thatt 2 V,tr >t 1 V,tr >t V , beingt 1 V,tr andt 2 V,tr the maximum times of the virus corresponding to η 1 p and η 2 p , respectively. Remark 5. According to Theorem 3.2, R(t tr ) should be compared to 1 + α(t tr ), not to 1, to obtain η c p (t tr ) and η c β (t tr ). However, as stated in Remark 2, the correction factor α(t tr ) is significantly smaller than 1 for the considered period of time (when t tr is smaller thant V ), so it was disregarded for the sake of simplicity. The effect of α(t tr ) may be significant only for t tr close tot V and, in such case, the viral dynamic can be slightly different from the one prescribed by Theorem 4.1 (and Lemma 1). Remark 6. Item (iii) of Theorem 4.1 establishes just the existence of t e >ť V such that for treatments starting at t tr ∈ (ť V , t e ], the new virus peak time is larger than the one corresponding to the untreated case, i.e.,t V,tr >t V . However, it should be noted that for parameters coming from real patient data, (the maximal) t e is indeed close tot V . This means that the time period where treatments can be ineffective is in most of the cases similar to (ť V ,t V ), i.e., similar to the time period where the virus is growing. Figures in Section 6 confirm this fact. A main consequence of item (iii) of Theorem 4.1 is that early treatments, if no effective, are largely more dangerous than late ones. Another critical point to be remarked is that when an early treatment is not strong enough to avoid the virus spreadability right after t tr , the greater the antiviral effectiveness η p (or η β ) is, the more is the time the virus remains in the host, since the maximum timet V,tr is delayed, as established in item (iv). As a result, antivirals could be detrimental as treated patients would need to be isolated for larger periods of time than untreated ones. Note that even when virus peak time can be delayed for some treatments, the virus peak will be always smaller than the one without any treatment. Furthermore, the fraction of dead cells at the end of the infection (D) will be always greater if no antiviral is administrated. Since D = 1 − U ∞ /U (t tr ), if we consider initial conditions at treatment time in equation 3.4, and being U tr c = U (t tr )/R(t tr ), it results and W (·) is the Lambert function (W (·) = W p (·), see [23] ). Consequently, if treatment is started early, such that R(t tr ) ≫ K(t tr ), then the fraction of dead cells can be approximated as D = 1 + W (−R(ttr )e −R(t tr ) ) , which is equal to 0 if R(t tr ) ≤ 1. Note that, by definition, W (−R(t tr )e −R(ttr) ) = −R(t tr ) for R(t tr ) ≤ 1, so D = 1 + (−R(t tr )/R(t tr )) = 0. On the other hand, if R(t tr ) > 1 then W (−R(t tr )e −R(ttr) ) ∈ (−1, 0] is monotonically increasing with R(t tr ) (see Figure 1 , [23] ). Hence, the fraction of dead cells at the end of infection is a monotonically increasing function of R(t tr ), for R(t tr ) > 1. Moreover, as the treatment time is delayed, K(t tr ) grows, being D a monotonically increasing function of R(t tr ), even for R(t tr ) ≤ 1. Theorem 4.1 describes the behavior of the virus under the effect of an inhibitor reducing the infection rate β or the replication rate p. If both effects (η β and η p ) are simultaneously included in the model, it can be computed a region -in the η β , η p space -for which condition R(t tr ) < 1 is fulfilled. This way, instead of independent critical values η c β (t tr ) and η c p (t tr ) corresponding to each parameter, there is an entire set of critical combinations that makes a treatment effective. This set depends on treatment time t tr and is placed on the boundary of the effective set Clearly, every pair (η β , η p ) ∈ H c (t tr ) fulfills condition R(t tr ) < 1 and, reciprocally, every pair (η β , η p ) / ∈ H c (t tr ) fulfills condition R(t tr ) > 1. Figure 4 shows a plot of set H c (t tr ) in the plane (η β × η p ), corresponding to parameters β = 0.5, δ = 0.2, p = 2 and c = 5, with U (t tr ) = 3. As it can be seen, for every inhibition effect pair (η β , η p ) ∈ H c (t tr ) (i.e. a point inside the red region in Figure 4 ) the antiviral treatment is ineffective. On the other hand, as it is shown in Theorem 4.1, for every pair (η β , η p ) such that η β > η c β (t tr ) or η p > η c p (t tr ) (the yellow region in Figure 4 ) the antiviral treatment is effective. Finally, for pairs in the region inside H c (t tr ) with η β < η c β (t tr ) and η p < η c p (t tr ) (which does not fit conditions in Theorem 4.1 and it is represented by the blue region in Figure 4 ) the antiviral treatment is still effective. In this section, the parameters of model (2.1) are estimated using viral load data of 9 RT-PCR COVID-19 positive patients, labeled as A,B,C,D,E,F,G,H and I, reported by Woelfel et. al. [22] . We follow a similar procedure as in Vargas et. al. [12] . Since the viral load is measured in Log10 scales, the model fitting was fulfilled by minimizing the root mean squared of logarithmic error (RMSLE), denoted as: where n is the number of measurements, y i the model predictive output, andȳ i the experimental measurement. Since the minimization of 5.1 implies a nonlinear optimization problem, with highly dependence on initial conditions, the Differential Evolution (DE) algorithm [43, 24] is employed as a global optimization algorithm, which has shown to be robust to initial guesses of parameters [44] . Even though it is still debatable which compartments SARS-CoV-2 can infect, there is a common agreement that the viral shedding take places mainly in the respiratory epithelial cells (due to the high expression of ACE2) with direct viral toxicity of the infected cells [45] . Therefore, following previous works of mathematical modelling for influenza infection in humans, the value of U 0 is taken as about 4 × 10 8 cells for all patients [16] . Furthermore, I 0 is assumed to be 0 and V 0 was estimated (using a regression model, since the viral at the day of infection was not provided) [12] to be about 0.31 Copies/mL. Moreover, in order to avoid identifiability problems related with the fact that only viral titters are used to fit the model, the viral clearance parameter (c) was set in 2.4 1/day, which is in accordance with previous estimates for influenza and HIV [46, 16] . The parameters and initial condition (at the time of infection t = 0) of each patient are collected in Table 1 . Since the viral load was measured after the onset of the symptoms, an incubation period of 7 days post infection (dpo) was assumed for the time of infection, according to [12] . The time evolution of U , I and V is shown in Figure 5 , for each patient. As it can be seen, the plot confirms the results in Theorem 3.2 concerning the minimum and maximum times of V , the maximum time of I and the time when U reaches U c (i.e., when R(t) reaches 1). Table 2 , for the nine simulated patients. Figure 5 : U ,I,V time evolution for the untreated case. As stated in Theorem 3.2,ťV η c p (t tr )), the difference of viral loads at time-to-peak (∆V ) is above the 2 logs threshold [13] and the duration of infection (DI) is below the 30 days limit (according [51] the viral shedding interval for untreated COVID-19 patients is in order of 30 days) which is in accordance with an effective viral clearance strategy. On the other hand, for ineffective antiviral therapy (η p < η c p (t tr )), even tough ∆V is monotonically increasing with η p , the duration of infection is increased to a sub-potent drug efficacy. This means that the delay of the virus peak associated to ineffective treatments is significant in terms of the infected-related metrics. Figures 9 and 10 show the virus load evolution when the antiviral therapy is started in the course of viral spreading, at t tr ≈ 0.7t e and t tr ≈ t e , respectively. The viral load over the time has the same qualitative behavior than in the previous case. However, the duration of the infection is longer as the inhibition effect approaches η c p (t tr ) from below and from above (i.e.: η 3 p and η 4 p cases, violet and green lines in Figures p (t tr ) , the viral duration interval is augmented -even for effective therapies -since V has already reached a relatively high value at the treatment time. This behavior is confirmed in box-plots 11 and 12, where a sudden increase of the duration of infection happens when the antiviral efficacy is near the critical value. However, as the treatment time is delayed this behavior is mitigated (see box-plot 12) due to the natural increment of V (t tr ) (recall thaṫ V (t) ≈ (R(t tr ) − 1)δV (t), for t > t tr , so larger values of V (t tr ) produce larger values of |V (t)|). It is important to remark that, even when an increased duration of the viral shedding is reported for the effective treatment case in the boundary of critical drug effectiveness (η p ≈ η c p ), the viral load peak occurs previous tot V , in accordance with items i and ii of Theorem 4.1. In order to analyze the viral kinetics when the antiviral therapy is initiated at any time in the whole infection period (i.e., before and aftert V ), we studied the temporal dependence of infection-related metrics corresponding to fixed sup-potent/potent drug effectiveness. Only two representative patients (labeled as B and E) were considered, based on the uncertainty analysis made in Section 5. The treatment initial times were: t tr1 = 4, t tr2 = 6, t tr3 = 9, t tr4 = 17, t tr5 = 20 and t tr6 = 25 dpi. Figures 13 and 14 (left) show that if an ineffective treatment is initiated (η pB = 0.73 for patient B and η pE = 0.54 for patient E, with η c pB (t tr ) ≈ 0.81 and η c pE (t tr ) ≈ 0.6 for t tr < t e ), the time-to-peak (t V,tr ) and the duration of infection (DI) decrease as the treatment time is delayed. This can be explained by the fact that, for the same effectiveness,t V,tr is reduced as V (t tr ) is augmented. Equations (8.4) and (8.5) in Lemma 1 show that for a fixed R ≥ 1, k 1 (R) ≥ 0 and k 2 (R) ≤ 0 are increasing functions of V (t tr ) (i.e.: k 1 (R) = 0 and k 2 (R) = −1/(δ(R − 1)) for V (t tr ) → 0 while k 1 (R) = 1/((1 − R) 2 + R) and k 2 (R) = −1/(δR) for V (t tr ) → δ/β, being δ/β < V (t V )). Therefore, sincet V,tr = k 2 ln(k 1 ) + t tr (according to equation (8. 3)), it can be inferred thatt V,tr is monotonically decreasing with V (t tr ). Moreover, comparing the viral load at the time-to-peak, it can be deduced that V (t V,tr2 ) > V (t V,tr1 ) for an ineffective therapy started at two treatment times t tr2 > t tr1 during the beginning of the infection (assuming that U (t tr1 ) ≈ U (t tr2 )). By following similar steps as in Lemma 1, the viral load at the time-to-peak can be written as: V (t V,tr ) = V (t tr ) + (p/c)U (t tr ) − (δ/β)(ln(R tr ) + 1) and, therefore, However, from Figures 13 and 14 (right) it can be seen that V (t V,tr ) is of the order of 10 6 and 10 5 copies/ml for patients B and E, respectively, independently of the treatment initiation time. This can be explained by the fact that the difference of viral load att V,tr , for therapies started at different times, depends mainly on the deviation between the viral loads at treatment times, which normally are several order of magnitude below V (t V,tr ). For example, for patient B, V (t V,tr1 ) = 3.29 × 10 5 , V (t V,tr2 ) = 3.30 × 10 5 and V (t V,tr3 ) = 4.35 × 10 5 Copies/ml while V (t tr1 ) = 10 2 , V (t tr2 ) = 2.5 × 10 3 and V (t tr3 ) = 1.74 × 10 5 Copies/ml. Consequently, the increment on the viral peak is not significant as the treatment is delayed, although the duration of infection is considerably reduced (i.e.: from 96 to 55 days for patient B and 95 to 65 days for patient E). Note that the target cell-model assumes that the viral clearance in the convalescent phase is proportional to the virus load concentration at time-to-peak, which is in the same order of magnitude for the three cases. As a result, and taking into account that the viral peak is reached early as the treatment is delayed, a quickly viral deletion is observed for the postponed case. As a consequence, if a fixed sub-potent drug is employed, delaying the treatment initiation time could reduce viral shedding interval, without significantly increasing the viral load at time-to-peak. It is important to remark that if η p is reduced even more (η p ≪ η c ), the viral at time-to-peak follows the same behavior, although, the viral shedding interval is not-considerably decreased, sincet V,tr ≈t V as η → 0 (t tr ∈ (ť V ,t V ). Hence, although a non-significant improvement on the duration of infection is achieved if the treatment is delayed, the viral outcomes continues to be acceptable. On the other hand, if the ineffective therapy is initiated after the viral load peak, the duration of infection is slightly reduced with respect to the previous case, since R(t tr ) < 1 at this time and, therefore,V = (R(t tr ) − 1)δV (t) is a decreasing function of V (t tr ). In contrast to this, Figures 13 and 14 (right) show that if an effective antiviral therapy is applied (η pB = 0.9 for patient B and η pE = 0.8 for patient E) the duration of the infection is still decreased, since R 1 (t tr4 ) < R 2 (t tr4 ) for both, patient B and patient E, being R i the within-host basic reproduction number under a treatment with inhibition effect η i p , being η 1 p = 0.9 and η 2 p = 0.73 for patient B and η 1 p = 0.8 and η 2 p = 0.54 for patient E. Finally, the virus behavior was considered when a combined antiviral therapy inhibiting both, the viral infection rate (β) and the viral replication rate (p), was applied. Since the critical drug efficacy for acute models is defined during the viral spreading interval (Section 4), the treatment was initiated at t tr = 0.7t e , which is a value fulfilling t tr ∈ (ť V ,t V ). For the sake of clarity, only Patient A is considered and the 3 previous infection-related metrics are assessed as functions of the antiviral inhibition effects η p and η β . Figure 15 shows that the antiviral is effective for every inhibition effect pair (η β , η p ) fulfilling (η β , η p ) ∈ H c (t tr ) (i.e.: yellow region of ∆V ), in accordance with the results in Section 4.2. Moreover, as for the single inhibition cases, the duration of infection and the time-to-peak increase as the combined drug efficacy pair (η β , η p ) tends to the boundary of H c (t tr ). The difference of viral load at time-to-peak ∆V remains constant for every (η β , η p ) ∈ H c (t tr ) since V (t V,tr ) = t tr for effective treatments. In conclusion, the synergistic effect of drug effectiveness in combined therapies produces a reduction on the critical effectiveness with respect to single-therapies cases, with the same dynamical behavior over the boundary of H c (t tr ). While several vaccines have been developed to prevent COVID-19 disease, it is imperative to evaluate potential therapies against SARS-CoV-2 infection. Among them, antiviral treatments are promissory strategies to increment the viral clearance "within-host", decreasing disease severity. In this sense, the drug effectiveness concept is crucial to evaluate the drug effect threshold above which the viral load starts declining [52] . Although this critical value has been described for chronic infections (e.g. HIV [52, 53] , HCV [35] ) it has not been studied yet for COVID-19. The critical drug efficacy can be understood in terms of the antiviral potency to decline viral spreading, in spite of guiding the system to an uninfected equilibrium, as it was introduced in Definition 4, Section 4.2. In addition, the critical inhibition effect of an antiviral depends on the treatment initiation time, and it has shown to be a monotonically decreasing function during the viral spreading interval (roughly speaking, during the time interval before the untreated virus peak). Regarding the virus behavior for effective therapies (η > η c ), the viral load at time-to-peak is practically equal to V (t tr ) (i.e., a treatment is considered effective if the virus starts to decrease at the very moment the treatment is initiated, by modifying either η p , η β , or both), so ∆V is larger for earlier treatments, being greater than the 2 log threshold for effective antiviral therapies started at t tr < t e (t e ≈ 0.75t V ). Nevertheless, for η approaching η c (from above), the viral shedding interval is enlarged as the treatment is initiated during the infection growth. Therefore, if the therapeutic objective is to reduce both, the viral shedding interval and the viral peak, the efficacy level would need to overpass the critical value in a given quantity. From Figure 3 it can be seen that η c (t tr ) > 0.7 for most of patients. Simulations results suggest that for ineffective therapies, the virus would take longer to be clearedrather than a monotonic decline, as in the previous case -reaching a peak and finally decreasing to zero. In spite of the fact that the viral load at time-to-peak decreases monotonically with η (∆V increases as the inhibition effect jumps from 0 to η > 0), the time-to-peak increases as η approaches η c (from below), which results in a longer duration of infection, potentially requiring additional isolation measures for the treated patient. Although an effective reduction of the viral load peak and the duration of infection could be achieved with early treatments (treatments started before the untreated peak), minor effects are attained with late ones. Particularly, Figures 13 and 14 corroborate a slight reduction on the viral shedding interval if a subpotent drug therapy is employed after the time-to-peak. Consequently, taking into account that the viral load in COVID-19 patients presumably reaches the peak prior to the symptom onset, no further clinical improvements may be obtained if the therapy is started in this symptomatic phase (i.e.: notice that SARS-CoV-2 pathophysiology is characterized by a direct cytotoxic effect, endothelial cell damage, dysregulation of immune response, among others [45] ). Furthermore, considering the analysis presented in Theorem 4.1 that is valid during viral spreading interval, we can argue that the non-significant antiviral effect reported recently in [54] might be related to an early time-to-peak of COVID-19 patients. The effectiveness of combined treatments affecting both, η p and η β , was also studied and an interdependent critical drug efficacy level was computed. Mathematically, the critical combination of values of η p and η β is placed on the boundary of the effective set H c (t tr ), which is a set in the η p , η β space. In comparison with single treatment cases (represented by the horizontal and vertical dash-dot lines in Figure 15 ), a reduced critical antiviral efficacy was reported for the combined case, denoting a reduction on the necessary drug effectiveness to reduce viral spreading. Moreover, the viral characteristic behavior in the vicinity of the critical drug efficacy (i.e.: increase of time-to-peak and duration of infection) was preserved for the combined case, as the pair (η β , η p ) belongs to the critical boundary of H c (t tr ), which implies that the antiviral effectiveness characterization made in Theorem 4.1 for single treatments could be extended to combined therapies. In sum, this work formalizes the existence of a critical drug efficacy for acute infection models, which could have implications in the extended viral shedding observed "in-silico" by [55] (for SARS-CoV-2 infections) and by [56] (for influenza) when the antiviral therapy is initiated early but with a sub-potent drug efficacy. Moreover, it was shown the importance of initialization the antiviral therapy early (before viral load peak) in order to achieve a significant reduction of ∆V and DI [13, 57] . Although a time dependence was noticed for the critical drug efficacy (η c p (t), η c β (t)), since it is a decreasing function of t (Figure 3 ), its behavior does not compromise the antiviral success if an effective therapy is started later. The main clinical implications for acute infections, and, particularly, for the SARS-CoV-2 infection are: a) importance of viral load monitoring on probably infected COVID-19 patients (prophylactic use of antiviral therapy, previous to onset of symptoms, although adverse effects have been reported for potential antiviral drugs [36] , which could limited their prophylactic usage in risk patients), b) isolation of treated patient, c) possible explanation of the increase of duration of infection showed in immune compromised COVID-19 patients. 8. Appendix 1. Technical lemmas Lemma 1. Consider (4.1), constrained by the positive set X, at the beginning of the infection t = 0, with U (0) > U c , I(0) ≥ 0 and V (0) > 0. Consider that at some time t tr > 0, η p (t) jumps from 0 to η p > η c p , being η c p the critical value defined in (4.4) . Then, there exists t e (η p , t tr ) such that if t tr ∈ (ť V , t e ], the virus peak timet V,tr (considering the treatment effect) is a decreasing function of R(t tr ). Proof: Consider the approximation 3.5, in Remark 4. Since η p (t) jumps from 0 to η p < η c p , at t tr , then R(t) jumps from R(t − tr ) to R(t tr ), with R(t tr ) ∈ (R(t − tr ), 1) and R(t − tr ) > 1. Then it is possible to approximate the explicit solutions for U (t) and V (t) (by approximating the ln(z) function in the time interval before the virus peak by (z − 1)( w1 z + w 2 ), being w 1 and w 2 arbitrary constants, fulfilling w 1 + w 2 = 1 [58] . So, U (t), for t > t tr , can be written as A reasonable approximation, however, can be obtained by selecting w 1 = 0 and w 2 = 1 (also w 1 = 0.2 and w 1 = 0.8 gives a good result, but clearly the former selection significantly simplifies the expressions). In such a case, A, B, C, k N ttr and k D ttr read: The time at which U (t) reaches U tr ci.e., the time at which R(t) reaches 1 and V (t) reaches its peak, denoted ast V,tr (witht V,tr ≥ t tr ) -can be explicitly computed aŝ t V,tr = k 2 ln(k 1 ) + t tr , being U tr c = cδ βp(1−ηp) the critical value for U corresponding to the treatment parameter p(1 − η p ). Now, recalling that R(t tr ) = U(ttr ) U tr c , and denoting U (t tr ), V (t tr ) and R(t tr ) as U , V and R, respectively, for the sake of simplicity, k 1 , k 2 can be rewritten as: This way,t V,tr =t V,tr (R) = k 2 (R) ln(k 1 (R)) + t tr represents the time of the virus peak in terms of R. Note thatt V,tr (R) is defined only for R ≥ 1; indeed,t V,tr (1) = t tr since k 1 (1) = 1, whilet V,tr (R) > t tr for R > 1. The idea now is to consider the derivative oft V,tr with respect to R, to show that it is negative for treatment times t tr small enough. This derivative reads: (8.7) Since ∂k2 ∂R > 0 for R > 1, condition ∂tV,tr ∂R < 0 can be written as Furthermore, given that ln(·) is an increasing function on (0, ∞], it follows that Then, by replacing (8.4), (8.5), (8.6) and (8.7) in inequality (8.9), we have: Now, for R > 1 the exponent is negative, so function (1−R) 2 + β δ RV starts at the positive value (1 − R) 2 e −2 , for V = 0, then increases to a maximum and finally decreases asymptotically to zero, for V → ∞. So, there exists some interval of V , maybe small, such that V < f (V ). Figure 16 shows a plot of f (V ) for different values of R > 1. Finally, since we are considering the treatment time to belong to the increasing period of V (t) (i.e., t tr ∈ (ť V ,t V ), with V (ť V ) ≈ 0, then small values of V (t) correspond to small values of t. So, a time interval (ť V , t e ] exists such thatt V,tr is a decreasing function of R(t tr ), and the proof is complete. Figure 17 shows the time evolution of R(t) when the antiviral treatment is initiated at 0.75t V and different antiviral inhibition effects are considered, for the real data patients simulated in Sections 5 and 6. As it can be seen, larger values of η p (or smaller values of R(t tr )) corresponds always with larger values oft tr,V . Coronavirus disease 2019 (COVID-19) Situation Reports COVID-19 Dashboard by the Center for Systems Science and Engineering Cardiovascular implications of COVID-19 versus influenza infection: a review Use of antiviral drugs to reduce COVID-19 transmission, The Lancet Global Health Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 Translation: Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review Bioavailability of hydroxychloroquine tablets in healthy volunteers -host Modelling of COVID-19 Kinetics in Humans Timing of antiviral treatment initiation is critical to reduce SARS-Cov-2 viral load. medrxiv A SIDARTHE model of COVID-19 Epidemic in Italy Modelling SARS-CoV-2 Dynamics: Implications for Therapy Kinetics of influenza A virus infection in humans Effects of Aging on Influenza Virus Infection Dynamics Ebola Virus Infection Modelling and Identifiability Problems Modeling HIV persistence, the latent reservoir, and viral blips Modeling the within-host dynamics of HIV infection Modeling viral spread Virological assessment of hospitalized patients with COVID-2019 Characterization of SARS-CoV-2 Dynamics in the Host Modeling and Control of Infectious Diseases in the Host: With MATLAB and R In-host modeling Dynamics of HIV infection of CD4+ T cells An in vivo pharmacokinetic/pharmacodynamic model for antiretroviral combination Influenza virus population dynamics in the respiratory tract of experimentally infected mice Influenza A virus infection kinetics: quantitative data and models Passivity-based inverse optimal impulsive control for Influenza treatment in the host The role of antibody in enhancing dengue virus infection Modelling original antigenic sin in dengue viral infection Quantifying the effect of Vpu on the promotion of HIV-1 replication in the humanized mouse model Virus dynamics: mathematical principles of immunology and virology Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-ncov) in vitro Quantifying the effect of remdesivir in rhesus macaques infected with SARS-CoV-2, Virology Assessing bioavailablility of drug delivery systems: mathematical modeling Understanding the within-host dynamics of influenza A virus: from theory to clinical implications Neuraminidase inhibitors for treatment of human and avian strain influenza: A comparative modeling study Differential evolution-a simple efficient adaptive scheme for global optimization A comparative study of differential evolution algorithms for parameter fitting procedures Extrapulmonary manifestations of COVID-19 Modeling the three stages in HIV infection Temporal dynamics in viral shedding and transmissibility of COVID-19 Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 Respiratory disease in rhesus macaques inoculated with SARS-CoV-2 Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood The duration of viral shedding of discharged patients with severe COVID-19 HIV-1 infection and low steady state viral loads Modeling hiv dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity Repurposed antiviral drugs for COVID-19 interim WHO SOLIDARITY trial results Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response The mechanisms for within-host influenza virus control affect model-based assessment and prediction of antiviral treatment Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19) Estimating Hidden Asymptomatics, Herd Immunity Threshold and Lockdown Effects using a COVID-19 Specific Model